Solriamfetol Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of solriamfetol during breastfeeding. However, amounts in breastmilk appear to be low and would not be expected to cause any adverse effects in breastfed infants. If solriamfetol is required by the mother, it is not a reason to discontinue breastfeeding. Monitor the breastfed infant for adverse reactions, such agitation, insomnia, and reduced weight gain.
Drug Levels
Maternal Levels. The manufacturer reports that a single-dose milk and plasma lactation study was conducted in 6 healthy adult lactating women who were between 10 days and 52 weeks postpartum. They were administered a single oral 150 mg dose of solriamfetol. The daily infant dose is 0.112 mg/kg based on infant weight of 6 kg. The cumulative median amount excreted in breastmilk was 0.67 mg over 72 hours, which is about 5.5% of the weight-adjusted maternal dose. Of the total amount of solriamfetol excreted in breastmilk over 72 hours, approximately 78% and 98% were excreted by 8 and 24 hours, respectively, with an apparent mean elimination half-life in breast milk of about 5 hours.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
